Covid-19 roundup: Mod­er­na en­lists Catal­ent as man­u­fac­tur­ing part­ner, se­cur­ing fill-fin­ish ca­pac­i­ty for the first 100M dos­es

With Phase III tri­als now out­lined, lock­ing in a net­work of pro­duc­tion part­ners ap­pears to be top of mind for the lead­ing Covid-19 vac­cine de­vel­op­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.